Report
Onward Medical NV - BCI dialogue with FDA intensifying
• As only the 2nd BCI company, ONWD announced its acceptance into the FDA's new Total Product Lifecycle Advisory Program (TAP): this program aims to help bridge the so-called valley of death from technology concept to commercialization. This acceptance, combined with the recently received Breakthrough Device Designation, clearly signals the FDA's support for ONWD's ARC-BCI ongoing and future development plans. • We welcome this news as the clinical path forward for ARC-BCI is currently rather blurry due to its innovativeness. Remember that all currently ongoing work with ARC-BCI is grant-funded and in collaboration with Clinatec. Upon successful completion of early
Underlying
ONWARD MEDICAL NV
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.